Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.

Franco TrevisaniGiovanni BrandiFrancesca GarutiMaria Aurelia BarberaRaffaella TortoraAndrea Casadei GardiniAlessandro GranitoFrancesco TovoliStefania De LorenzoAndrea Lorenzo InghilesiFrancesco Giuseppe FoschiMauro BernardiFabio MarraRodolfo SaccoGiovan Giuseppe Di Costanzo

Published in: Journal of cancer research and clinical oncology (2017)

MC may be an efficient and safe second-line systemic therapy for HCC patients who discontinued sorafenib for toxicity or tumor progression.

Keyphrases

poor prognosis
oxidative stress
randomized controlled trial
locally advanced
clinical trial
squamous cell carcinoma
radiation therapy
phase iii